Phenotyping of malignant hematopoietic cells

Summary 1255 cases of leukemia-lymphoma were tested between 1972 and 1984 by multiple marker analysis. Routine leukemia phenotyping was performed using standard morphological and cytochemical techniques in combination with clinical and histo-pathological information; the main emphasis was put on immunological surface marker analysis using erythrocyte rosette assays, TdT and a large panel of poly- and monoclonal antibody tests. The 1255 cases were divided into these major types and subtypes: 349 cases of ALL and related immature T- and Burkitt-lymphomas (cALL, pre B-ALL, B-ALL and Burkitt-lymphomas, T-ALL and immature, mostly leukemic T-lymphomas, Null-ALL), 454 cases of mature T- and B-cell malignancies (T-CLL, mycosis fungoides, Sezary-syndrome, T-lymphomas, B-CLL, hairy cell leukemia, multiple myeloma, B-lymphomas), 263 cases of acute myeloid leukemias (AML, AMMoL/AMoL), 182 cases of chronic myeloid leukemias (CML in chronic phase, CMoL, CML in blast crisis), 6 cases of erythroleukemia and 1 case of megakaryoblastic leukemia. A simplified classification scheme which has been used in our laboratories is presented. Phenotyping is of diagnostic, prognostic and therapeutic relevance, most evidently for patients with ALL. Routine leukemia phenotyping should be performed with highly standardized techniques and reagents and by combining information from several fields in the multiple marker analysis. New areas of leukemia research might become very useful for the routine procedure of phenotyping.Abbreviations ALL acute lymphoblastic leukemia - AML acute myeloblastic leukemia - AMMoL acute myelomonoblastic leukemia - AMoL acute monoblastic leukemia - cALL common ALL - CLL chronic lymphocytic leukemia - CML chronic myelocytic leukemia - CML-BC CML in blastic crisis - CMoL chronic monocytic leukemia     

Haploidentical Hematopoietic Stem Cell Transplantation in Leukemia’s: Experience from a Cancer Center in India

There has been a surge in haploidentical hematopoietic stem cell transplantation (HSCT) in India recently. However, there is a paucity of data on haploidentical HSCT from India. The report is an analysis of data of haploidentical HSCT performed at our center. Analysis of patients with acute leukemia or chronic myeloid leukemia who underwent haploidentical HSCT during 2014–2019 was performed. The graft versus host disease (GVHD) prophylaxis was post-transplant Cyclophosphamide with Mycophenolate-mofetil and Cyclosporine. All patients were transfused peripheral blood stem cells from donors. Overall survival (OS) was calculated using the Kaplan–Meier method. Twenty-one patients underwent haploidentical HSCT. Fourteen-patients were males. The median age of patients was 15 years. Fludarabine with total body irradiation was the most common conditioning regimen (n = 15, 71.4%). The median duration for neutrophil and platelet engraftment was 14 days. Cumulative incidence of acute and chronic GVHD was 19%, and 38% respectively. The median follow-up was 26 months and the two-year OS was 38%. Twelve (57%) patients died during the study period, 8 patients (38%) died from transplant-related mortality (TRM), and 4 from disease relapse. Sepsis was the cause of death in six of the eight TRM. Nine out of 21 patients (42.8%) are leukemia-free on follow-up. Haploidentical HSCT is a promising modality of treatment in patients who have no suitable matched donors. Though the TRM remains high, good disease control was achieved in 42.8% of patients. Multi-drug resistant bacterial infection remains a challenge in performing haploidentical HSCT in developing countries.     

急性白血病患者雌激素受体多药耐药相关蛋白的检测及临床意义

目的 :探讨雌激素受体 (ER)、多药耐药相关蛋白 (MRP)表达与临床疗效的关系 ,为耐药白血病寻找新的治疗途径。方法 :采用免疫组化ABC法检测了 37例急性白血病 (AL)复发难治患者骨髓单个核细胞的ER与MRP表达。结果 :①ER阳性组CR率为 91.6 7% (11/ 12 ) ,阴性组为 2 8.0 0 % (7/ 2 5 ) ,ER阳性组CR率显著优于阴性组 (P <0 .0 1)。②MRP阳性组CR率为 2 3.81% (5 / 2 1) ,MRP阴性组为 81.2 5 % (13/ 16 ) ,MRP阳性组CR率明显差于阴性组 (P <0 .0 1)。③ 37例AL患者中 ,8例ER +/MRP -与 17例ER - /MRP +患者其ER与MRP表达的一致性很好 (Kappa系数 =0 .83,P <0 .0 1)。另有ER +/MRP +4例 ,ER - /MRP - 8例 ,其ER与MRP表达缺乏一致性。结论 :ER与MRP表达有一定的一致性 ,且与临床疗效有一定关系 ;ER与MRP检测有助于疗效和预后的判定     

Stimulatory effect on DNA synthesis of thymus and spleen extract from leukemic AKR mice

Summary A 30,000–50,000 molecular weight (MW) extract of thymus and spleen from 11 age groups of untreated AKR mice, 1–210 days old, was tested for in vitro effect on thymide incorporation into normal AKR lymph node cells, normal spleen cells, and leukemic thymocytes. Extracts from mice up to 5 months of age mostly had slightly inhibitory effect but concomitant with emergence of thymus leukemia in the 6-month-old mice, the extract acquired a strongly mitogenic effect on normal lymph node cells. Seven-month-old, non-leukemic animals again yielded extracts with inhibitory effect.Supported by the US Health Education and Welfare grant no. IROI CA 26109-01, Commission of the European Communities contract no. 251-77-1 BIO DK, and The Carlsberg Foundation     

Antibiotic strategy after the empiric phase in patients treated for a hematological malignancy

 Empiric broad-spectrum antibiotic therapy has become a generally accepted strategy in the treatment of febrile neutropenic patients. Particularly in patients with prolonged neutropenia, subsequent adaptation of such a regimen will be the rule rather than exception. Since there are no uniformly accepted guidelines for the modification of antibiotic therapy during the post-empiric phase, we assessed the impact of a set of rules that evolved during the first randomized trials. Evaluation of the clinician's compliance with these rules in 1951 febrile neutropenic episodes was the subject of the present analysis. Treatment was modified in 761 (39%) cases, and these changes were made according to the rules in 76%. For 75% of the alterations in treatment during the evening and night shifts, no reasonable explanation was established, while 93% of the modifications during the normal working hours were made for objective reasons. The empiric regimen was more frequently changed in patients with a clinical focus of infection at the onset of fever than in patients who showed fever as the only symptom of a possible infection. The perceived need for modification amounted to 69% in pulmonary infections, to 51% in skin and soft-tissue infections, to 44% in patients with abdominal complaints, and to 37% in upper respiratory tract infections. Glycopeptides constituted 22% of modifications, particularly in patients with a central venous catheter, and systemically active antifungals were administered in 16% of cases. Especially inexperienced clinicians tend to adjust antibiotic therapy, in spite of the fact that persistence of fever alone seldom reflects inadequate treatment when the clinical condition of the patient is stable or improving. On the other hand, the development of subsequent infectious events emphasizes that a genuine need for modification does frequently exist. Received: 4 December 1995 / Accepted: 7 December 1995     

DAPTO等方案诱导治疗急性双表型白血病11例报告

报告１１例急性双表型白血病的诱导化疗结果。５例ＡＢＬ经ＤＡＰＴＯ方案诱导化疗，４例于２８－５０天内完全缓解，持续ＣＲ时间７－１４月，存活时间８－１８月，１例仍无病生存，其余６例应用ＤＶＰ等方案化疗，ＣＲ２例，持续ＣＲ分别为４和８月，６例患者作１例生存１６月外，余未超过７月。     

177例慢性粒细胞白血病患者血糖测定值分析

目的 探讨可能影响慢性粒细胞白血病（CML）患者血糖测定值的因素，加深对白血病假性低血糖现象的认识。方法 应用自动生化分析仪对177例CML患者血糖和外周血白细胞进行测定，并结合临床进行分析。结果 在177例CML患者中，共发现32例（18.1%)白血病假性低血糖现象。血糖测定值与白细胞计数呈负相关（P＜0.05)，环境温度对假性低血糖现象的发生也有一定的影响。32例白血病假性低血糖现象中，24例未得到临床医师的充分认识。此外，5例（2.8%)CML急变合并高血糖患者，其原因可能是应激导致了血糖增高。结论 外周血白细胞计数和环境温度对白血病假性低血糖现象的产生有一定作用，对CML血糖值的分析应与临床症状相结合。     

急性髓系白血病患者诱导缓解治疗期症状群的纵向研究

目的 探讨急性髓系白血病（acute myeloid leukemia,AML）患者诱导缓解治疗（induction therapy,IT）期症状群的变化情况。方法 2018年1月—2020年6月,便利选取山东省某三级甲等医院血液内科首次确诊为AML并接受IT的130例患者,运用中文版记忆症状评估量表在IT开始前1 d（T1）、IT结束当天（T2）、IT结束后第7天（T3）对其进行评估,运用因子分析确立症状群的组成。 结果 T1存在4个症状群,为心理症状群、营养症状群、神经症状群和疼痛-出汗症状群。T2存在3个症状群,为胃肠道症状群、疲乏症状群和治疗相关症状群。T3存在4个症状群,为心理症状群、胃肠道症状群、疲乏症状群和形象改变症状群。其中心理症状群在T1和T3存在,疲乏症状群和胃肠道症状群在T2和T3持续存在。结论 AML患者在IT期经历的症状群呈动态变化。IT前的心理症状群、IT中的胃肠道症状群、IT结束后的疲乏症状群可作为优先干预的症状群。     

Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies

BackgroundData on convalescent plasma therapy (CPT) in patients of hematological malignancies with severe Covid-19 is scarce.ObjectiveTo study 14-day mortality in patients who received CPT.Patients & methodsRetrospective multicentre observational study conducted in 4 centres treating haematological malignancies across Delhi-national capital region. Total 33 haematological malignancies patients with severe Covid-19 who received CPT were analysed.ResultsThe median age of the study cohort was 62 years (18–80 years). Twenty one percent patients had 1 comorbidity, 18 % had 2 comorbidities and 6% patients had 3 and 5 comorbidities each. Twenty four patients were on active therapy. Sixty nine percent of patients required ICU stay. Twenty five patients received plasma therapy within 7 days (early) of diagnosis of Covid-19 infection. Median day of plasma infusion from date of diagnosis of Covid-19 infection was 4 days (range: 2–25 days). Patient who had early initiation of plasma therapy had shorter duration of hospitalisation (12.7 vs 24.3 days, p = 0.000). Overall mortality in the cohort was 45.5%. There was no effect of disease status, active therapy, presence of comorbidity on mortality. There was no difference in the mortality in patients receiving early vs late initiation of plasma therapy or in patients receiving one versus two plasma therapy.ConclusionsWe provide a large series of patients with hematological malignancies and role of CPT in this group.